KDventures says Umecrine Cognition receives two US patent allowances for second-generation GAMSA compounds

Reuters2026/09/07 07:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

KDventures said Umecrine Cognition received two USPTO Notices of Allowance covering second-generation GAMSA compounds GR3053 and GR3055.
The patents are expected to provide US New Chemical Entity protection through at least 2042.
The compounds broaden Umecrine Cognition’s platform in neurodegenerative diseases, alongside clinical candidate golexanolon.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

KDventures says Umecrine Cognition receives two US patent allowances for second-generation GAMSA compounds

You may also like

Crypto prices